Spruce Biosciences, Inc. SPRB
46.20 USD -0.46 (-1.00%)
At closeNov 11, 2026, 4:00 PM EST
46.20 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
45.44 Day range 47.37
38.06 52-week range 127.90
- YTD
- -46.96%
- 1 year
- -58.99%
News
benzinga.com Spruce Biosciences Q3 EPS $(8.51) Up From $(14.58) YoY Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(8.51) per share. This is a 41.63 percent increase over losses of $(14.58) per share from the same period last year.
businesswire.com Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
benzinga.com Spruce Biosciences Separates CRHX-101 Program Into Adrenyx Biosciences, Plans Spin-Off To Stockholders Transaction Expected to Create Two Independent, Publicly Traded Companies with Distinct Strategic Priorities, Separate Capital Structures and Dedicated TeamsUp to $50 Million Committed to Adrenyx…
businesswire.com Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
businesswire.com Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
businesswire.com Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
businesswire.com Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
benzinga.com Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target Citizens analyst Jonathan Wolleben reiterates Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and maintains $144 price target.- benzinga.com Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149 Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $149.
businesswire.com Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
gurufocus.com Spruce Biosciences Announces Launch of MPS3BStudy.com Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disor
benzinga.com Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type B Website Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory StudyTA-ERT EAP and…
businesswire.com Spruce Biosciences Announces Launch of MPS3BStudy.com SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
businesswire.com Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…- benzinga.com Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104 Guggenheim analyst Debjit Chattopadhyay maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $123 to $104.
benzinga.com Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144 Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.- benzinga.com SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q2 EPS $(6.68) Misses $(5.80) Estimate SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(6.68) per share which missed the analyst consensus estimate of $(5.80) by 15.17 percent. This is a 90.86…
gurufocus.com Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disord
businesswire.com Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
businesswire.com Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological…
businesswire.com Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and…
businesswire.com Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and…- benzinga.com B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160 B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $160.
businesswire.com Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
seekingalpha.com Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy Spruce Biosciences offers a high-risk, high-reward opportunity as it advances TA-ERT, potentially the first disease-modifying therapy for MPS IIIB, toward FDA approval. TA-ERT demonstrated durable…- benzinga.com Spruce Biosciences Joins Russell 3000 Index, Effective June 29 Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical…
gurufocus.com Spruce Biosciences Joins the Russell 3000® Index Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological diso
businesswire.com Spruce Biosciences Joins the Russell 3000® Index SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
businesswire.com Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
benzinga.com Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123 Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $123.
businesswire.com Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
benzinga.com Jones Trading Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $135 Jones Trading analyst Catherine Novack initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $135.- benzinga.com Spruce Biosciences Presents Data Demonstrating Long-Term Benefit Of Tralesinidase Alfa Enzyme Replacement Therapy In Patients With Sanfilippo Syndrome Type B At 18th International MPS Symposium Data Highlight TA-ERT's Potential as the First Disease-Modifying Treatment Option for MPS IIIB, a Fatal Condition With No Approved TherapiesTreatment With Weekly TA-ERT Demonstrated Rapid and Durable…
- benzinga.com HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $200 to $150.
benzinga.com Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $150 Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $170 to $150.- benzinga.com SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q1 EPS $(8.94) Misses $(8.78) Estimate SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(8.94) per share which missed the analyst consensus estimate of $(8.78) by 1.82 percent. This is a 62.75…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Stock Market Today: Dow Jones, S&P 500 Futures Edge Higher With Eyes On Iran Talks—Apple, UnitedHealth, 3M In Focus (UPDATED) (Editor’s note: The futures and ETFs data were updated.) U.S. stock futures rose on Tuesday following Monday's decline. Futures of major benchmark indices edged up, with negotiating teams from the…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Amazon Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Amazon Inc (NASDAQ: AMZN) rose in pre-market trading after announcing a strategic collaboration with Anthropic to spend $100B on AWS.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket 
benzinga.com Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session